AZ D910GC00001 "Matterhorn"

Gastrointestinal - Matterhorn

AZ D910GC00001 "Matterhorn"

Objective

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Principal Investigator(s)
Hugo Hool, MD

Clinical Trial Categories

  • UCLA Trio Clinical Trials